Literature DB >> 20852128

Mutation of inhibitory helix-loop-helix protein Id3 causes γδ T-cell lymphoma in mice.

Jun Li1, Takashi Maruyama, Pin Zhang, Joanne E Konkel, Victoria Hoffman, Brian Zamarron, Wanjun Chen.   

Abstract

Human γδ T-cell lymphoma is a rare clinicopathologic entity with aggressive course and poor prognosis. The etiology and pathogenesis of γδ T-cell lymphoma is unknown. We show here that mice with deficiency in inhibitory helix-loop-helix protein Id3 (Id3(-/-)) developed γδ T-cell lymphoma that resembled human γδ T-cell lymphoma. The Id3(-/-) mice with lymphoma showed splenomegaly, hepatomegaly, and lymphadenopathy with involvement of bone marrow, thymus, kidney, and lungs between 6 and 15 months of age. Phenotypic analysis revealed that lymphomatous cells were cluster of differentiation (CD)3(+), γδ T-cell receptor (TCR)(+), and αβ TCR(-), and expressed CD8(+)CD4(-), CD4(+)CD8(-), or a mixture of the two. Id3(-/-) γδ T-cell lymphoma used predominantly Vγ1.1, some Vγ3, yet no Vγ2 TCR, and some showed increased levels of the oncogene c-Myc. Strikingly, adoptive transfer of the γδ T-cell lymphoma into syngeneic Rag1(-/-) mice resulted in aggressive γδ T-cell lymphoma, identical to the Id3(-/-) donor. Thus, our data demonstrate that Id3 regulates the development of γδ T-cell lymphoma in mice, raising a possibility of Id3 gene mutation in human γδ T-cell lymphoma. Our model will provide a tool for studying the molecular mechanisms and development of human γδ T-cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20852128      PMCID: PMC3031408          DOI: 10.1182/blood-2010-03-274506

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

Review 1.  The structure, function, and molecular genetics of the gamma/delta T cell receptor.

Authors:  D H Raulet
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

2.  Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins.

Authors:  X H Sun; N G Copeland; N A Jenkins; D Baltimore
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

3.  Id: a negative regulator of helix-loop-helix DNA binding proteins. Control of terminal myogenic differentiation.

Authors:  R Benezra; R L Davis; A Lassar; S Tapscott; M Thayer; D Lockshon; H Weintraub
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

4.  High incidence of T-cell tumors in E2A-null mice and E2A/Id1 double-knockout mice.

Authors:  W Yan; A Z Young; V C Soares; R Kelley; R Benezra; Y Zhuang
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

5.  The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3.

Authors:  V Riechmann; I van Crüchten; F Sablitzky
Journal:  Nucleic Acids Res       Date:  1994-03-11       Impact factor: 16.971

6.  E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas.

Authors:  G Bain; I Engel; E C Robanus Maandag; H P te Riele; J R Voland; L L Sharp; J Chun; B Huey; D Pinkel; C Murre
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

Review 7.  Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia.

Authors:  Clemens Grabher; Harald von Boehmer; A Thomas Look
Journal:  Nat Rev Cancer       Date:  2006-05       Impact factor: 60.716

8.  Id3 restricts the developmental potential of gamma delta lineage during thymopoiesis.

Authors:  Ikuko Ueda-Hayakawa; Josh Mahlios; Yuan Zhuang
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

Review 9.  Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.

Authors:  Karim Belhadj; Felix Reyes; Jean-Pierre Farcet; Herve Tilly; Christian Bastard; Regis Angonin; Eric Deconinck; Frederic Charlotte; Veronique Leblond; Eric Labouyrie; Pierre Lederlin; Jean-Francois Emile; Beatrice Delmas-Marsalet; Bertrand Arnulf; Elie-Serge Zafrani; Philippe Gaulard
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  21 in total

1.  Helix-loop-helix factor inhibitor of differentiation 3 regulates interleukin-5 expression and B-1a B cell proliferation.

Authors:  Heather M Perry; Stephanie N Oldham; Shawn P Fahl; Xuchu Que; Ayelet Gonen; Daniel B Harmon; Sotirios Tsimikas; Joseph L Witztum; Timothy P Bender; Coleen A McNamara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-10-10       Impact factor: 8.311

Review 2.  ID'ing innate and innate-like lymphoid cells.

Authors:  Mihalis Verykokakis; Erin C Zook; Barbara L Kee
Journal:  Immunol Rev       Date:  2014-09       Impact factor: 12.988

Review 3.  The ID proteins: master regulators of cancer stem cells and tumour aggressiveness.

Authors:  Anna Lasorella; Robert Benezra; Antonio Iavarone
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

4.  Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.

Authors:  Julia Richter; Matthias Schlesner; Steve Hoffmann; Markus Kreuz; Ellen Leich; Birgit Burkhardt; Maciej Rosolowski; Ole Ammerpohl; Rabea Wagener; Stephan H Bernhart; Dido Lenze; Monika Szczepanowski; Maren Paulsen; Simone Lipinski; Robert B Russell; Sabine Adam-Klages; Gordana Apic; Alexander Claviez; Dirk Hasenclever; Volker Hovestadt; Nadine Hornig; Jan O Korbel; Dieter Kube; David Langenberger; Chris Lawerenz; Jasmin Lisfeld; Katharina Meyer; Simone Picelli; Jordan Pischimarov; Bernhard Radlwimmer; Tobias Rausch; Marius Rohde; Markus Schilhabel; René Scholtysik; Rainer Spang; Heiko Trautmann; Thorsten Zenz; Arndt Borkhardt; Hans G Drexler; Peter Möller; Roderick A F MacLeod; Christiane Pott; Stefan Schreiber; Lorenz Trümper; Markus Loeffler; Peter F Stadler; Peter Lichter; Roland Eils; Ralf Küppers; Michael Hummel; Wolfram Klapper; Philip Rosenstiel; Andreas Rosenwald; Benedikt Brors; Reiner Siebert
Journal:  Nat Genet       Date:  2012-11-11       Impact factor: 38.330

5.  Deficiency of a transcriptional regulator, inhibitor of differentiation 3, induces glomerulonephritis in apolipoprotein E-deficient mice: a model linking hyperlipidemia and renal disease.

Authors:  Harini Bagavant; Yogesh Scindia; Dominika Nackiewicz; Seshagiri Rao Nandula; Amanda Doran; Alexis Cutchins; Stephanie Oldham; Umesh Deshmukh; Coleen McNamara
Journal:  Am J Pathol       Date:  2011-06-14       Impact factor: 4.307

6.  Id2 Collaborates with Id3 To Suppress Invariant NKT and Innate-like Tumors.

Authors:  Jia Li; Sumedha Roy; Young-Mi Kim; Shibo Li; Baojun Zhang; Cassandra Love; Anupama Reddy; Deepthi Rajagopalan; Sandeep Dave; Anna Mae Diehl; Yuan Zhuang
Journal:  J Immunol       Date:  2017-03-03       Impact factor: 5.422

7.  The osteopontin transgenic mouse is a new model for Sjögren's syndrome.

Authors:  Sehba Husain-Krautter; Jill M Kramer; Wentian Li; Benchang Guo; Thomas L Rothstein
Journal:  Clin Immunol       Date:  2015-01-05       Impact factor: 3.969

Review 8.  Mouse Models of Primary Sjogren's Syndrome.

Authors:  Young-Seok Park; Adrienne E Gauna; Seunghee Cha
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 9.  E proteins in lymphocyte development and lymphoid diseases.

Authors:  Ian Belle; Yuan Zhuang
Journal:  Curr Top Dev Biol       Date:  2014       Impact factor: 4.897

Review 10.  Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells.

Authors:  Sumedha Roy; Yuan Zhuang
Journal:  Front Med       Date:  2018-07-24       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.